Search

Your search keyword '"Fowler, Nathan H."' showing total 592 results
Start Over Author "Fowler, Nathan H."
592 results on '"Fowler, Nathan H."'

1. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial

Author

Gurumurthi, Ashwath, Chin, Collin K., Feng, Lei, Fowler, Nathan H., Strati, Paolo, Hagemeister, Fredrick B., Fayad, Luis E., Westin, Jason R., Obi, Chizobam, Arafat, Janine, Nair, Ranjit, Steiner, Raphael E., Neelapu, Sattva S., Flowers, Christopher R., and Nastoupil, Loretta J.

Published
2024
Full Text
View/download PDF

2. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Author

Salles, Gilles, Schuster, Stephen J., Dreyling, Martin, Fischer, Luca, Kuruvilla, John, Patten, Piers E. M., von Tresckow, Bastian, Smith, Sonali M., Jiménez-Ubieto, Ana, Davis, Keith L., Anjos, Carla, Chu, Jufen, Zhang, Jie, Lobetti Bodoni, Chiara, Thieblemont, Catherine, Fowler, Nathan H., Dickinson, Michael, Martínez-López, Joaquin, Wang, Yucai, and Link, Brian K.

Published
2022
Full Text
View/download PDF

4. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Cherng, Hua-Jay J., Sun, Ryan, Sugg, Bryant, Irwin, Russell, Yang, Haopeng, Le, Cao Cuong, Deng, Qing, Fayad, Luis, Fowler, Nathan H., Parmar, Simrit, Steiner, Raphael, Hagemeister, Fredrick, Nair, Ranjit, Lee, Hun Ju, Rodriguez, Maria, Samaniego, Felipe, Iyer, Swaminathan P., Flowers, Christopher R., Wang, Linghua, Nastoupil, Loretta J., Neelapu, Sattva S., Ahmed, Sairah, Strati, Paolo, Green, Michael R., and Westin, Jason

Published
2022
Full Text
View/download PDF

5. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo

Published
2022
Full Text
View/download PDF

7. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Author

Schuster, Stephen J., primary, Fowler, Nathan H., additional, Dickinson, Michael, additional, Martinez-Lopez, Joaquin, additional, Kolstad, Arne, additional, Butler, Jason, additional, Ghosh, Monalisa, additional, Popplewell, Leslie, additional, Chavez, Julio C., additional, Bachy, Emmanuel, additional, Kato, Koji, additional, Harigae, Hideo, additional, Kersten, Marie José, additional, Andreadis, Charalambos, additional, Riedell, Peter A., additional, Ho, P Joy, additional, Pérez-Simón, José Antonio, additional, Chen, Andy I., additional, Nastoupil, Loretta J., additional, von Tresckow, Bastian, additional, Ferreri, Andres Jose Maria, additional, Teshima, Takanori, additional, Patten, Piers EM, additional, McGuirk, Joseph P., additional, Petzer, Andreas, additional, Offner, Fritz, additional, Viardot, Andreas, additional, Zinzani, Pier Luigi, additional, Malladi, Ram, additional, Zia, Aiesha, additional, Awasthi, Rakesh, additional, Paule, Ines, additional, Germano, Davide, additional, Ramos, Roberto, additional, Hsu, Pei, additional, Thieblemont, Catherine, additional, and Dreyling, Martin, additional

Published
2024
Full Text
View/download PDF

8. Long-Term Durable Responses in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL) Treated with Tisagenlecleucel and Its Association with Persistence of Chimeric Antigen Receptor (CAR) T Cells

Author

Awasthi, Rakesh, primary, Waldron, Edward, additional, Grupp, Stephan A., additional, Pulsipher, Mike A., additional, Bader, Peter, additional, Schuster, Stephen J., additional, Maziarz, Richard T., additional, Waller, Edmund K., additional, Jager, Ulrich, additional, Thieblemont, Catherine, additional, Dreyling, Martin, additional, Fowler, Nathan H., additional, Maier, Harald Jakob, additional, and Willert, Jennifer, additional

Published
2024
Full Text
View/download PDF

9. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

10. Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update

Author

Dreyling, Martin, primary, Fowler, Nathan H, additional, Dickinson, Michael, additional, Martínez-López, Joaquín, additional, Kolstad, Arne, additional, Butler, Jason, additional, Ghosh, Monalisa, additional, Popplewell, Leslie, additional, Chavez, Julio C., additional, Bachy, Emmanuel, additional, Kato, Koji, additional, Harigae, Hideo, additional, Kersten, Marie José, additional, Andreadis, Charalambos Babis, additional, Riedell, Peter A., additional, Ho, P. Joy, additional, Perez-Simon, Jose Antonio, additional, Chen, Andy I, additional, Nastoupil, Loretta J, additional, von Tresckow, Bastian, additional, Ferreri, Andrés JM, additional, Teshima, Takanori, additional, Patten, Piers EM, additional, McGuirk, Joseph P, additional, Petzer, Andreas L., additional, Offner, Fritz, additional, Viardot, Andreas, additional, Zinzani, Pier Luigi, additional, Malladi, Ram, additional, Paule, Ines, additional, Zia, Aiesha, additional, Awasthi, Rakesh, additional, Han, Xia, additional, Germano, Davide, additional, O'Donovan, Darragh Stephen, additional, Ramos, Roberto Javier, additional, Maier, Harald J., additional, Masood, Aisha, additional, Thieblemont, Catherine, additional, and Schuster, Stephen J., additional

Published
2024
Full Text
View/download PDF

11. Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Author

Fowler, Nathan H, Cheah, Chan Yoon, Gascoyne, Randy D, Gribben, John, Neelapu, Sattva S, Ghia, Paolo, Bollard, Catherine, Ansell, Stephen, Curran, Michael, Wilson, Wyndham H, O'Brien, Susan, Grant, Cliona, Little, Richard, Zenz, Thorsten, Nastoupil, Loretta J, and Dunleavy, Kieron

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Hematology, Rare Diseases, Cancer, Lymphoma, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Animals, B-Lymphocytes, Biomarkers, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Humans, Immunotherapy, Leukemia, B-Cell, Lymphoma, B-Cell, Molecular Targeted Therapy, Neoplasm Grading, Neoplasm Staging, Signal Transduction, Tumor Escape, Tumor Microenvironment, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

The tumor microenvironment is the cellular and molecular environment in which the tumor exists and with which it continuously interacts. In B-cell lymphomas, this microenvironment is intriguing in that it plays critical roles in the regulation of tumor cell survival and proliferation, fostering immune escape as well as the development of treatment resistance. The purpose of this review is to summarize the proceedings of the Second Annual Summit on the Immune Microenvironment in Hematologic Malignancies that took place on September 11-12, 2014 in Dublin, Ireland. We provide a timely overview of the composition and biological relevance of the cellular and molecular microenvironment interface and discuss the role of interactions between the microenvironment and neoplastic cells in a variety of B-cell lymphomas. In addition, we focus on various novel therapeutic strategies that target the tumor microenvironment, including agents that modulate B-cell receptor pathways and immune-checkpoints, chimeric antigen receptor T cells and immunomodulatory agents.

Published
2016

12. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Author

Gordon, Max J., primary, Feng, Lei, additional, Strati, Paolo, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Samaniego, Felipe, additional, Marques‐Piubelli, Mario L., additional, Vega Vazquez, Francisco, additional, Parra Cuentas, Edwin R., additional, Solis‐Soto, Luisa M., additional, Ma, Wencai, additional, Wang, Jing, additional, Claret, Linda, additional, Averill, Barbara, additional, Ibanez, Karina, additional, Fayad, Luis E., additional, Flowers, Christopher R., additional, Green, Michael R., additional, Davis, R. Eric, additional, Neelapu, Sattva S., additional, Fowler, Nathan H., additional, and Nastoupil, Loretta J., additional

Published
2023
Full Text
View/download PDF

14. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

Author

Nastoupil, Loretta J, Lunning, Matthew A, Vose, Julie M, Schreeder, Marshall T, Siddiqi, Tanya, Flowers, Christopher R, Cohen, Jonathon B, Burger, Jan A, Wierda, William G, O'Brien, Susan, Sportelli, Peter, Miskin, Hari P, Purdom, Michelle A, Weiss, Michael S, and Fowler, Nathan H

Published
2019
Full Text
View/download PDF

15. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Author

Strati, Paolo, primary, Li, Xubin, additional, Deng, Qing, additional, Marques-Piubelli, Mario L., additional, Henderson, Jared, additional, Watson, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Yang, Haopeng, additional, Ravanmehr, Vida, additional, Fayad, Luis E., additional, Iyer, Swaminathan P., additional, Nastoupil, Loretta J., additional, Hagemeister, Frederick B., additional, Parra, Edwin R., additional, Saini, Neeraj, additional, Takahashi, Koichi, additional, Fowler, Nathan H., additional, Westin, Jason R., additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Flowers, Christopher R., additional, Wang, Linghua, additional, Ahmed, Sairah, additional, Al-Atrash, Gheath, additional, Vega, Francisco, additional, Neelapu, Sattva S., additional, and Green, Michael R., additional

Published
2023
Full Text
View/download PDF

19. Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Author

Zinzani, Pier Luigi, primary, Rodgers, Thomas, primary, Marino, Dario, primary, Frezzato, Maurizio, primary, Barbui, Anna Maria, primary, Castellino, Claudia, primary, Meli, Erika, primary, Fowler, Nathan H., primary, Salles, Gilles, primary, Feinberg, Bruce, primary, Kurukulasuriya, Nuwan C., primary, Tillmanns, Sascha, primary, Parche, Stephan, primary, Dey, Debarshi, primary, Fingerle-Rowson, Günter, primary, Ambarkhane, Sumeet, primary, Winderlich, Mark, primary, and Nowakowski, Grzegorz S., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Author

Zinzani, Pier Luigi, primary, Rodgers, Thomas, primary, Marino, Dario, primary, Frezzato, Maurizio, primary, Barbui, Anna Maria, primary, Castellino, Claudia, primary, Meli, Erika, primary, Fowler, Nathan H., primary, Salles, Gilles, primary, Feinberg, Bruce, primary, Kurukulasuriya, Nuwan C., primary, Tillmanns, Sascha, primary, Parche, Stephan, primary, Dey, Debarshi, primary, Fingerle-Rowson, Günter, primary, Ambarkhane, Sumeet, primary, Winderlich, Mark, primary, and Nowakowski, Grzegorz S., primary

Published
2023
Full Text
View/download PDF

21. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Author

Fanale, Michelle A., Cheah, Chan Yoon, Rich, Amy, Medeiros, L.Jeffrey, Lai, Chao-Ming, Oki, Yasuhiro, Romaguera, Jorge E., Fayad, Luis E., Hagemeister, F.B., Samaniego, Felipe, Rodriguez, Maria A., Neelapu, Sattva S., Lee, Hun J., Nastoupil, Loretta, Fowler, Nathan H., Turturro, Francesco, Westin, Jason R., Wang, Michael L., McLaughlin, Peter, Pinnix, Chelsea C., Milgrom, Sarah A., Dabaja, Bouthaina, Horowitz, Sandra B., and Younes, Anas

Published
2017
Full Text
View/download PDF

22. Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

25. Matching-Adjusted Indirect Comparison of Efficacy and Safety for Tisagenlecleucel and Mosunetuzumab in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL)

Author

Fowler, Nathan H., primary, Schuster, Stephen J., additional, Yang, Hongbo, additional, Xiang, Cheryl, additional, Ramos, Roberto, additional, Maier, Harald, additional, Anjos, Carla, additional, Jousseaume, Etienne, additional, Thieblemont, Catherine, additional, and Dreyling, Martin, additional

Published
2023
Full Text
View/download PDF

27. Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Batlevi, Connie Lee, primary, Nos, Grigorii, additional, Kotlov, Nikita, additional, Sorokina, Maria, additional, Okwali, Michelle, additional, Bagaev, Alexander, additional, Michaud, Laure, additional, Shah, Gunjan L., additional, Shouval, Roni, additional, Alarcon Tomas, Ana, additional, Ewalt, Mark D., additional, Belova, Ekaterina, additional, Degryse, Sandrine, additional, Tazearslan, Cagdas, additional, Podsvirova, Svetlana, additional, Love, Anna Mooney, additional, Postovalova, Ekaterina, additional, Fowler, Nathan H., additional, Perales, Miguel-Angel, additional, Schoder, Heiko, additional, Dogan, Ahmet, additional, Arcila, Maria E., additional, Salles, Gilles, additional, and Sauter, Craig S., additional

Published
2022
Full Text
View/download PDF

28. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL

Author

Nair, Ranjit, primary, Ayers, Amy, additional, Nastoupil, Loretta J., additional, Gunther, Jillian R., additional, Fayad, Luis, additional, Fowler, Nathan H., additional, Miranda, Roberto N., additional, Hagemeister, Fredrick B., additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, Steiner, Raphael, additional, Strati, Paolo, additional, Nieto, Yago, additional, Ramdial, Jeremy L., additional, Chihara, Dai, additional, Wang, Michael L., additional, Malpica Castillo, Luis E, additional, Saini, Neeraj, additional, Jain, Preetesh, additional, Pinnix, Chelsea C., additional, Dabaja, Bouthaina S., additional, Green, Michael R, additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Marques-Piubelli, Mario L., additional, Vega, Francisco, additional, Noorani, Mansoor, additional, Ahmed, Sairah, additional, Westin, Jason, additional, Neelapu, Sattva S., additional, Feng, Lei, additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2022
Full Text
View/download PDF

29. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Author

Li, Xubin, primary, Deng, Qing, additional, Henderson, Jared, additional, Watson, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Fayad, Luis, additional, Iyer, Swaminathan Padmanabhan, additional, Hagemeister, Fredrick B., additional, Nastoupil, Loretta J., additional, Fowler, Nathan H., additional, Westin, Jason, additional, Steiner, Raphael, additional, Nair, Ranjit, additional, Ahmed, Sairah, additional, Alatrash, Gheath, additional, Neelapu, Sattva S., additional, Strati, Paolo, additional, and Green, Michael R, additional

Published
2022
Full Text
View/download PDF

30. Integrated Genomic and Transcriptomic Analysis Provides Molecular Characterization of Distinct Clonal Evolution Pathways during Follicular Lymphoma Transformation

Author

Almog, Nava, primary, Novokreshchenova, Anna, additional, Smirnova, Sofia, additional, Brown, Jessica H., additional, Kotlov, Nikita, additional, Meerson, Mark, additional, Anosov, Ilya, additional, Akpek, Gorgun, additional, Ayrons, Keith, additional, Fowler, Nathan H., additional, and Ferguson, Kevin, additional

Published
2022
Full Text
View/download PDF

31. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

Author

Agbedia, Owhofasa O., primary, Prakash, Rishab, additional, Xu, Jie, additional, Becnel, Melody R., additional, Nair, Ranjit, additional, Steiner, Raphael E, additional, Feng, Lei, additional, Lee, Hun Ju, additional, Strati, Paolo, additional, Ahmed, Sairah, additional, Parmar, Simrit, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Westin, Jason, additional, Nastoupil, Loretta J., additional, Vo, Ann, additional, Samaniego, Felipe, additional, Fowler, Nathan H., additional, Saini, Neeraj, additional, Khouri, Issa F., additional, Im, Jin S., additional, Fayad, Luis, additional, Jain, Preetesh, additional, Wang, Michael L., additional, Miranda, Roberto N., additional, Vega, Francisco, additional, Medeiros, Jeffrey, additional, Oki, Yasuhiro, additional, Flowers, Christopher R., additional, Neelapu, Sattva S., additional, and Iyer, Swaminathan P., additional

Published
2022
Full Text
View/download PDF

32. Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Author

Dreyling, Martin, primary, Dickinson, Michael, additional, Martinez Lopez, Joaquin, additional, Kolstad, Arne, additional, Butler, Jason P, additional, Ghosh, Monalisa, additional, Popplewell, Leslie L., additional, Chavez, Julio, additional, Bachy, Emmanuel, additional, Kato, Koji, additional, Harigae, Hideo, additional, Kersten, Marie Jose, additional, Andreadis, Charalambos, additional, Riedell, Peter A., additional, Ho, Phoebe Joy, additional, Perez-Simon, Jose A., additional, Chen, Andy, additional, Nastoupil, Loretta J., additional, von Tresckow, Bastian, additional, Ferreri, Andrés J M, additional, Teshima, Takanori, additional, Patten, Piers E.M., additional, McGuirk, Joseph P., additional, Petzer, Andreas, additional, Offner, Fritz, additional, Viardot, Andreas, additional, Zinzani, Pier Luigi, additional, Malladi, Ram, additional, Paule, Ines, additional, Zia, Aiesha, additional, Awasthi, Rakesh, additional, Han, Xia, additional, Germano, Davide, additional, O'Donovan, Darragh, additional, Ramos, Roberto, additional, Masood, Aisha, additional, Thieblemont, Catherine, additional, Fowler, Nathan H., additional, and Schuster, Stephen J., additional

Published
2022
Full Text
View/download PDF

33. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Author

Jain, Preetesh, primary, Ok, Chi Young, additional, Fetooh, Ahmed, additional, Kanagal-Shamanna, Rashmi, additional, Jelloul, Fatima Zahra, additional, Hill, Holly, additional, Floyd, Kristen, additional, Loghavi, Sanam, additional, Zuo, Zhuang, additional, Yin, C. Cameron, additional, Routbort, Mark, additional, Tang, Guilin, additional, Ahmed, Sairah, additional, Malpica Castillo, Luis Enrique, additional, Siddiqui, Asiya, additional, Chen, Wendy, additional, Oriabure, Onyeka, additional, Badillo, Maria, additional, Steiner, Raphael E, additional, Iyer, Swaminathan P., additional, Lee, Hun Ju, additional, Luthra, Rajyalakshmi, additional, Vega, Francisco, additional, Flowers, Christopher R., additional, Medeiros, Jeffrey, additional, Wang, Michael L., additional, Patel, Keyur P., additional, Fowler, Nathan H., additional, and Nair, Ranjit, additional

Published
2022
Full Text
View/download PDF

34. Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin

Author

Elias, Alexandra, primary, Prakash, Rishab, additional, Nastoupil, Loretta J., additional, Fowler, Nathan H., additional, Ahmed, Sairah, additional, Nair, Ranjit, additional, Malpica Castillo, Luis Enrique, additional, Dabaja, Bouthaina S., additional, Xu, Jie, additional, Medeiros, Jeffrey, additional, Stewart, John, additional, Wang, Wei, additional, Pinnix, Chelsea C., additional, Hunt, Kelly, additional, Clemens, Mark W, additional, Miranda, Roberto N., additional, and Iyer, Swaminathan P., additional

Published
2022
Full Text
View/download PDF

35. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Author

Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

36. Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma

Author

Yu, Fang, He, Hua, Nastoupil, Loretta J, Xu-Monette, Zijun Y, Pham, Ky, Liang, Yong, Chen, Guang, Fowler, Nathan H, Yin, C Cameron, Tan, Dongfeng, Yang, Yaling, Hu, Shimin, Young, Ken H, Pham, Lan V, and You, M James

Subjects
Original Article
Abstract

FOXM1 is a transcription factor that controls cell cycle regulation, cell proliferation, and differentiation. Overexpression of FOXM1 has been implicated in various cancer types. However, the activation status and functional significance of FOXM1 in diffuse large B cell lymphoma (DLBCL) have not been well investigated. Using proteomic approaches, we discovered that the protein expression levels of FOXM1 and PLK1 were positively correlated in DLBCL cell lines and primary DLBCL. Expression levels of FOXM1 and PLK1 mRNAs were also significantly higher in DLBCL than in normal human B cells and could predict poor prognosis of DLBCL, particularly in patients with germinal center B cell-like (GCB) DLBCL. Furthermore, proteomic studies defined a FOXM1-PLK1 signature that consisted of proteins upstream and downstream of that axis involved in the p38-MAPK-AKT pathway, cell cycle, and DNA damage/repair. Further studies demonstrated a mechanistic function of the FOXM1/PLK1 axis in connection with the DNA damage response pathways regulating the S/G2 checkpoint of the cell cycle. Therapeutic targeting of FOXM1/PLK1 using a FOXM1 or PLK1 inhibitor, as well as other clinically relevant small-molecule inhibitors targeting ATR-CHK1, was highly effective in DLBCL in vitro models. These findings are instrumental for lymphoma drug discovery aiming at the FOXM1/PLK1/ATR/CHK1 axis.

Published
2022

37. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Author

Morschhauser, Franck, primary, Nastoupil, Loretta, additional, Feugier, Pierre, additional, Schiano de Colella, Jean-Marc, additional, Tilly, Hervé, additional, Palomba, Maria Lia, additional, Bachy, Emmanuel, additional, Fruchart, Christophe, additional, Libby, Edward N., additional, Casasnovas, Rene-Olivier, additional, Flinn, Ian W., additional, Haioun, Corinne, additional, Maisonneuve, Hervé, additional, Ysebaert, Loic, additional, Bartlett, Nancy L., additional, Bouabdallah, Kamal, additional, Brice, Pauline, additional, Ribrag, Vincent, additional, Le Gouill, Steven, additional, Daguindau, Nicolas, additional, Guidez, Stéphanie, additional, Pica, Gian Matteo, additional, García-Sancho, Alejandro Martín, additional, López-Guillermo, Armondo, additional, Larouche, Jean-François, additional, Ando, Kiyoshi, additional, Gomes da Silva, Maria, additional, André, Marc, additional, Kalung, Wu, additional, Sehn, Laurie H., additional, Izutsu, Koji, additional, Cartron, Guillaume, additional, Gkasiamis, Argyrios, additional, Crowe, Russell, additional, Xerri, Luc, additional, Fowler, Nathan H., additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

40. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, additional, Marques-Piubelli, Mario L., additional, Dai, Enyu, additional, Dang, Minghao, additional, Ma, Man Chun John, additional, Li, Xubin, additional, Yang, Haopeng, additional, Henderson, Jared, additional, Kudryashova, Olga, additional, Meerson, Mark, additional, Isaev, Sergey, additional, Kotlov, Nikita, additional, Nomie, Krystle J., additional, Bagaev, Alexander, additional, Parra, Edwin R., additional, Solis Soto, Luisa M., additional, Parmar, Simrit, additional, Hagemeister, Fredrick B., additional, Ahmed, Sairah, additional, Iyer, Swaminathan P., additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Fayad, Luis, additional, Lee, Hun, additional, Fowler, Nathan H., additional, Flowers, Christopher R., additional, Strati, Paolo, additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta J., additional, Vega, Francisco, additional, Wang, Linghua, additional, and Green, Michael R., additional

Published
2022
Full Text
View/download PDF

41. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Morschhauser, Franck, Nastoupil, Loretta, Feugier, Pierre, Schiano de Colella, Jean-Marc, Tilly, Hervé, Palomba, Maria Lia, Bachy, Emmanuel, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Le Gouill, Steven, Daguindau, Nicolas, Guidez, Stéphanie, Pica, Gian Matteo, García-Sancho, Alejandro Martín, López-Guillermo, Armondo, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Kalung, Wu, Sehn, Laurie H, Izutsu, Koji, Cartron, Guillaume, Gkasiamis, Argyrios, Crowe, Russell, Xerri, Luc, Fowler, Nathan H, Salles, Gilles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Morschhauser, Franck, Nastoupil, Loretta, Feugier, Pierre, Schiano de Colella, Jean-Marc, Tilly, Hervé, Palomba, Maria Lia, Bachy, Emmanuel, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Le Gouill, Steven, Daguindau, Nicolas, Guidez, Stéphanie, Pica, Gian Matteo, García-Sancho, Alejandro Martín, López-Guillermo, Armondo, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Kalung, Wu, Sehn, Laurie H, Izutsu, Koji, Cartron, Guillaume, Gkasiamis, Argyrios, Crowe, Russell, Xerri, Luc, Fowler, Nathan H, and Salles, Gilles

Abstract

JCO The RELEVANCE trial (ClinicalTrials.gov identifier: NCT01650701) showed that lenalidomide plus rituximab (R) provided similar efficacy to rituximab plus chemotherapy (R-chemo) in patients with advanced-stage, previously untreated follicular lymphoma (FL). We report the second interim analysis of the RELEVANCE trial after 6 years of follow-up. Patients with previously untreated grade 1-3a FL were assigned 1:1 to R or R-chemo, followed by rituximab maintenance. Coprimary end points were complete response (confirmed/unconfirmed) at week 120 and progression-free survival (PFS). At median follow-up of 72 months, 6-year PFS was 60% and 59% for R and R-chemo, respectively (hazard ratio = 1.03 [95% CI, 0.84 to 1.27]). Six-year overall survival was estimated to be 89% in both groups. Median PFS and overall survival were not reached in either group. Overall response after progression was 61% and 59%, and 5-year estimated survival rate after progression was 69% and 74% in the R and R-chemo groups, respectively. The transformation rate per year in the R and R-chemo groups was 0.68% and 0.45%, and secondary primary malignancies occurred in 11% and 13% ( = .34), respectively. No new safety signals were observed. R continues to demonstrate comparable, durable efficacy and safety versus R-chemo in previously untreated patients with FL and provides an acceptable chemo-free alternative.

Published
2022

43. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Author

Chihara, Dai, Fanale, Michelle A., Miranda, Roberto N., Noorani, Mansoor, Westin, Jason R., Nastoupil, Loretta J., Hagemeister, Fredrick B., Fayad, Luis E., Romaguera, Jorge E., Samaniego, Felipe, Turturro, Francesco, Lee, Hun J., Neelapu, Sattva S., Rodriguez, M. Alma, Wang, Michael, Fowler, Nathan H., Davis, Richard E., Medeiros, L. Jeffrey, Hosing, Chitra, Nieto, Yago L., and Oki, Yasuhiro

Published
2017
Full Text
View/download PDF

44. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Author

Wilson, Wyndham H., Young, Ryan M., Schmitz, Roland, Yang, Yandan, Pittaluga, Stefania, Wright, George, Lih, Chih- Jian, Williams, P. Mickey, Shaffer, Arthur L., Gerecitano, John, de Vos, Sven, Goy, Andre, Kenkre, Vaishalee P., Barr, Paul M., Blum, Kristie A., Shustov, Andrei, Advani, Ranjana, Fowler, Nathan H., Vose, Julie M., Elstrom, Rebecca L., Habermann, Thomas M., Barrientos, Jacqueline C., McGreivy, Jesse, Fardis, Maria, Chang, Betty Y., Clow, Fong, Munneke, Brian, Moussa, Davina, Beaupre, Darrin M., and Staudt, Louis M.

Subjects
Biological sciences, Health
Abstract

The two major subtypes of diffuse large B cell lymphoma (DLBCL)--activated B cell-like (ABC) and germinal center B cell-like (GCB)--arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling (1). The ABC subtype has a ~40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies (2). We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling. In a phase 1/2 clinical trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106). ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), especially those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways. However, the highest number of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms. These results support the selective development of ibrutinib for the treatment of ABC DLBCL., Nuclear factor kappa B (NF-κB) activity sustains viability of ABC, but not GCB, DLBCL cell lines (3) and is constitutively activated by signals from the BCR and MYD88 pathways (4,5). [...]

Published
2015

45. Assessment of Healthcare Resource Utilization (HCRU) and Hospitalization Costs in Patients (pts) with Relapsed or Refractory (r/r) Follicular Lymphoma (FL) Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study

Author

Fowler, Nathan H., primary, Dickinson, Michael, additional, Ghosh, Monalisa, additional, Chen, Andy I., additional, Andreadis, Charalambos, additional, Tiwari, Ranjan, additional, Masood, Aisha, additional, Ramos, Roberto, additional, Bollu, Vamsi, additional, Jousseaume, Etienne, additional, Thieblemont, Catherine, additional, Dreyling, Martin, additional, and Schuster, Stephen J., additional

Published
2022
Full Text
View/download PDF

46. Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase 2 Elara Study

Author

Thieblemont, Catherine, primary, Dickinson, Michael, additional, Martinez-Lopez, Joaquin, additional, Kolstad, Arne, additional, Butler, Jason, additional, Ghosh, Monalisa, additional, Popplewell, Leslie, additional, Chavez, Julio C., additional, Bachy, Emmanuel, additional, Kato, Koji, additional, Harigae, Hideo, additional, Kersten, Marie José, additional, Andreadis, Charalambos, additional, Riedell, Peter A., additional, Ho, P Joy, additional, Pérez-Simón, José Antonio, additional, Chen, Andy I., additional, Nastoupil, Loretta J., additional, von Tresckow, Bastian, additional, María Ferreri, Andrés José, additional, Teshima, Takanori, additional, Patten, Piers EM, additional, McGuirk, Joseph P., additional, Petzer, Andreas, additional, Offner, Fritz, additional, Viardot, Andreas, additional, Zinzani, Pier Luigi, additional, Malladi, Ram, additional, Zia, Aiesha, additional, Bodoni, Chiara Lobetti, additional, Masood, Aisha, additional, Schuster, Stephen J., additional, Fowler, Nathan H., additional, and Dreyling, Martin, additional

Published
2022
Full Text
View/download PDF

47. Comparative Efficacy and Safety of Tisagenlecleucel (tisa-cel) and Axicabtagene Ciloleucel (axi-cel) in Relapsed/ Refractory Follicular Lymphoma (r/r FL)

Author

Dickinson, Michael, primary, Martinez-Lopez, Joaquin, additional, Jousseaume, Etienne, additional, Anjos, Carla, additional, Yang, Hongbo, additional, Chai, Xinglei, additional, Xiang, Cheryl, additional, Wang, Travis, additional, Ramos, Roberto, additional, Lobetti-Bodoni, Chiara, additional, Schuster, Stephen J., additional, and Fowler, Nathan H., additional

Published
2022
Full Text
View/download PDF

48. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Author

Morschhauser, Franck, Nastoupil, Loretta, Feugier, Pierre, Schiano de Colella, Jean-Marc, Tilly, Hervé, Palomba, Maria Lia, Bachy, Emmanuel, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Le Gouill, Steven, Daguindau, Nicolas, Guidez, Stéphanie, Pica, Gian Matteo, García-Sancho, Alejandro Martín, López-Guillermo, Armondo, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Kalung, Wu, Sehn, Laurie H, Izutsu, Koji, Cartron, Guillaume, Gkasiamis, Argyrios, Crowe, Russell, Xerri, Luc, Fowler, Nathan H, Salles, Gilles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Abstract

JCO The RELEVANCE trial (ClinicalTrials.gov identifier: NCT01650701) showed that lenalidomide plus rituximab (R) provided similar efficacy to rituximab plus chemotherapy (R-chemo) in patients with advanced-stage, previously untreated follicular lymphoma (FL). We report the second interim analysis of the RELEVANCE trial after 6 years of follow-up. Patients with previously untreated grade 1-3a FL were assigned 1:1 to R or R-chemo, followed by rituximab maintenance. Coprimary end points were complete response (confirmed/unconfirmed) at week 120 and progression-free survival (PFS). At median follow-up of 72 months, 6-year PFS was 60% and 59% for R and R-chemo, respectively (hazard ratio = 1.03 [95% CI, 0.84 to 1.27]). Six-year overall survival was estimated to be 89% in both groups. Median PFS and overall survival were not reached in either group. Overall response after progression was 61% and 59%, and 5-year estimated survival rate after progression was 69% and 74% in the R and R-chemo groups, respectively. The transformation rate per year in the R and R-chemo groups was 0.68% and 0.45%, and secondary primary malignancies occurred in 11% and 13% ( = .34), respectively. No new safety signals were observed. R continues to demonstrate comparable, durable efficacy and safety versus R-chemo in previously untreated patients with FL and provides an acceptable chemo-free alternative.

Published
2022

49. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Author

Strati, Paolo, primary, Li, Xubin, additional, Deng, Qing, additional, Marques-Piubelli, Mario Luiz, additional, Henderson, Jared, additional, Balada, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Yang, Haopeng, additional, Ravanmehr, Vida, additional, Fayad, Luis E., additional, Iyer, Swaminathan, additional, Nastoupil, Loretta J., additional, Hagemeister, Fredrick B., additional, Fowler, Nathan H., additional, Westin, Jason R., additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Flowers, Christopher R., additional, Wang, Linghua, additional, Ahmed, Sairah, additional, Al-Atrash, Gheath, additional, Vega, Francisco, additional, Neelapu, Sattva S., additional, and Green, Michael, additional

Published
2022
Full Text
View/download PDF

50. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

Author

Balasubramanian, Sriram, primary, Hodkinson, Brendan, additional, Schuster, Stephen J., additional, Fowler, Nathan H., additional, Trotman, Judith, additional, Hess, Georg, additional, Cheson, Bruce D., additional, Schaffer, Michael, additional, Sun, Steven, additional, Deshpande, Sanjay, additional, Vermeulen, Jessica, additional, Salles, Gilles, additional, and Gopal, Ajay K., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results